Jacob Johnson
Stock Analyst at Stephens & Co.
(3.65)
# 783
Out of 4,876 analysts
77
Total ratings
47.46%
Success rate
8.48%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $238.79 | +0.51% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.73 | -10.85% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $8.19 | -26.74% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $30.59 | +96.14% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $198.80 | +58.45% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $408.28 | +66.55% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $123.56 | +37.58% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $5.11 | -2.15% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $2.20 | +400.00% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $24.64 | +54.22% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $7.41 | +129.42% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.42 | +76.06% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $51.84 | +67.82% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $218.87 | +78.19% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $7.17 | +151.05% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.39 | +151.05% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $21.49 | +34.95% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $114.15 | +13.89% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $150.01 | +151.32% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $238.79
Upside: +0.51%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.73
Upside: -10.85%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $8.19
Upside: -26.74%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $30.59
Upside: +96.14%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $198.80
Upside: +58.45%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $408.28
Upside: +66.55%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $123.56
Upside: +37.58%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $5.11
Upside: -2.15%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.20
Upside: +400.00%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $24.64
Upside: +54.22%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $7.41
Upside: +129.42%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.42
Upside: +76.06%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $51.84
Upside: +67.82%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $218.87
Upside: +78.19%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $7.17
Upside: +151.05%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.39
Upside: +151.05%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $21.49
Upside: +34.95%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $114.15
Upside: +13.89%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $150.01
Upside: +151.32%